Non-exclusive drug discount agreement for Dexamethasone (ATC S01BA01) via Open-House model
Original notice title
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Dexamethason (ATC-Code nach WHO: S01BA01)
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...
No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Feb 28, 2027
Overview
Weak opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Feb 2027
- Supply of Dexamethasone pharmaceutical products under a non-exclusive discount agreement.
- Participation in the Open-House model; no negotiations or exclusivity.
Show full summary
Non-exclusive drug discount agreement (Rabattvereinbarung) under §130a Abs. 8 SGB V for the active ingredient Dexamethasone (ATC S01BA01) via an Open-House model. Published by AOK PLUS for pharmaceutical companies. No guaranteed volumes; contract ends 28 February 2027. All qualified companies can participate during the participation period.
Risks
The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...
No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur as defined in §4 Abs. 18 AMG.
- Must accept the confidentiality and silence obligations regarding the agreement content.
Eligibility
- Must submit required declarations (exclusion grounds, Russia sanctions).
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive drug discount agreement for Dexamethasone (ATC S01BA01) via Open-House model
One lot covering all Dexamethasone pharmaceutical products. Open-house model: no exclusivity, no negotiations, no minimum volumes. Agreement valid until 28 February 2027.
Location
Duration
Category
Award Criteria
Deadline
Award details
Siehe Kurzbeschreibung
Show original TED data
Original lot title
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Dexamethason (ATC-Code nach WHO: S01BA01)
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 22 Dec 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 857590-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
30 / 100
Complexity
20 / 100
Risk factors
The buyer may end the open-house procedure early if exclusive discount agreements are signed, which typically occur 8–1...
No minimum volumes; actual demand depends on patient prescriptions and pharmacy choices, which is unpredictable.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications